Extended Data Table 5 Anti-tetanus antibodies in participants co-administered with tetanus vaccine at different time points after administration, with baseline antibody titers < 0.01 IU/mL

From: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial

  1. GMT, geometric mean titer.
  2. The GMTs are presented as the geometric mean (% coefficient of variation).
  3. The anti-tetanus antibody (polyclonal antibody) titers were measured using the HTIG PD bioanalytical method for both vaccine combination subgroups.
  4. The proportion of participants with anti-tetanus antibody ≥0.1 IU/mL were calculated, and the corresponding 95% CI was constructed using the Clopper–Pearson method. A 95% CI for intergroup difference was calculated using Miettinen–Nurminen method. A mixed-effect model for repeated measures was used to compare and analyze anti-tetanus antibody between groups at each scheduled time point. All tests were two-sided. No adjustments were made for multiple comparisons.
Back to article page